Does the media favor ICCM or NMTC?

In the previous week, IceCure Medical had 5 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for IceCure Medical and 1 mentions for NeuroOne Medical Technologies. IceCure Medical's average media sentiment score of 0.35 beat NeuroOne Medical Technologies' score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ICCM or CTSO?

In the previous week, IceCure Medical had 1 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for IceCure Medical and 5 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.98 beat IceCure Medical's score of 0.35 indicating that Cytosorbents is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytosorbents 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ICCM or PETV?

IceCure Medical currently has a consensus target price of $62.70, suggesting a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ICCM or PETV more profitable?

IceCure Medical has a net margin of -441.60% compared to PetVivo's net margin of -902.82%. IceCure Medical's return on equity of -211.73% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -441.60% -211.73% -119.13% PetVivo -902.82% -4,813.07% -281.78%

Does the media favor ICCM or PETV?

In the previous week, IceCure Medical had 4 more articles in the media than PetVivo. MarketBeat recorded 6 mentions for IceCure Medical and 2 mentions for PetVivo. IceCure Medical's average media sentiment score of 0.35 beat PetVivo's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer POAI or ICCM?

IceCure Medical has a consensus price target of $62.70, suggesting a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend ICCM or MODD?

IceCure Medical presently has a consensus target price of $62.70, indicating a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe IceCure Medical is more favorable than Modular Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

IceCure Medical (ICCM) Competitors

$5.40 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$5.47 +0.07 (+1.28%)

As of 06/18/2026 07:59 PM Eastern

Compare

ICCM vs. NMTC, CTSO, PETV, POAI, and MODD

Should you buy IceCure Medical stock or one of its competitors? MarketBeat compares IceCure Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IceCure Medical include NeuroOne Medical Technologies (NMTC), Cytosorbents (CTSO), PetVivo (PETV), Predictive Oncology (POAI), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry.

How does IceCure Medical compare to NeuroOne Medical Technologies?

IceCure Medical (NASDAQ:ICCM) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

NeuroOne Medical Technologies has a net margin of -68.35% compared to IceCure Medical's net margin of -441.60%. NeuroOne Medical Technologies' return on equity of -99.43% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IceCure Medical has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

IceCure Medical presently has a consensus target price of $62.70, suggesting a potential upside of 1,061.11%. NeuroOne Medical Technologies has a consensus target price of $11.67, suggesting a potential upside of 254.61%. Given IceCure Medical's higher possible upside, equities research analysts clearly believe IceCure Medical is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

NeuroOne Medical Technologies has higher revenue and earnings than IceCure Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.57M	4.25	-$15.06M	-$7.21	N/A
NeuroOne Medical Technologies	$12.10M	2.37	-$3.61M	-$0.85	N/A

In the previous week, IceCure Medical had 5 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for IceCure Medical and 1 mentions for NeuroOne Medical Technologies. IceCure Medical's average media sentiment score of 0.35 beat NeuroOne Medical Technologies' score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeuroOne Medical Technologies beats IceCure Medical on 9 of the 14 factors compared between the two stocks.

How does IceCure Medical compare to Cytosorbents?

IceCure Medical (NASDAQ:ICCM) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 7.3% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cytosorbents has a net margin of -31.85% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
Cytosorbents	-31.85%	-235.57%	-37.88%

In the previous week, IceCure Medical had 1 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for IceCure Medical and 5 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.98 beat IceCure Medical's score of 0.35 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytosorbents has higher revenue and earnings than IceCure Medical. Cytosorbents is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.57M	4.25	-$15.06M	-$7.21	N/A
Cytosorbents	$37.06M	0.74	-$8.20M	-$0.19	N/A

IceCure Medical has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

IceCure Medical presently has a consensus price target of $62.70, indicating a potential upside of 1,061.11%. Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 1,126.33%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than IceCure Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cytosorbents beats IceCure Medical on 10 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to PetVivo?

IceCure Medical (NASDAQ:ICCM) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 10.8% of PetVivo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IceCure Medical has a net margin of -441.60% compared to PetVivo's net margin of -902.82%. IceCure Medical's return on equity of -211.73% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
PetVivo	-902.82%	-4,813.07%	-281.78%

IceCure Medical has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

PetVivo has lower revenue, but higher earnings than IceCure Medical. PetVivo is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.57M	4.25	-$15.06M	-$7.21	N/A
PetVivo	$1.05M	27.86	-$10.95M	-$0.38	N/A

In the previous week, IceCure Medical had 4 more articles in the media than PetVivo. MarketBeat recorded 6 mentions for IceCure Medical and 2 mentions for PetVivo. IceCure Medical's average media sentiment score of 0.35 beat PetVivo's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical currently has a consensus target price of $62.70, suggesting a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

IceCure Medical beats PetVivo on 10 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

IceCure Medical has a net margin of -441.60% compared to Predictive Oncology's net margin of -5,065.23%. IceCure Medical's return on equity of -211.73% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
IceCure Medical	-441.60%	-211.73%	-119.13%

Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

In the previous week, IceCure Medical had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 6 mentions for IceCure Medical and 0 mentions for Predictive Oncology. IceCure Medical's average media sentiment score of 0.35 beat Predictive Oncology's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
IceCure Medical	Neutral

IceCure Medical has a consensus price target of $62.70, suggesting a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Predictive Oncology has higher earnings, but lower revenue than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.52	-$12.66M	-$13.50	N/A
IceCure Medical	$3.57M	4.25	-$15.06M	-$7.21	N/A

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

IceCure Medical beats Predictive Oncology on 11 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to Modular Medical?

IceCure Medical (NASDAQ:ICCM) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

IceCure Medical has higher revenue and earnings than Modular Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.57M	4.25	-$15.06M	-$7.21	N/A
Modular Medical	N/A	N/A	-$18.82M	-$14.71	N/A

IceCure Medical presently has a consensus target price of $62.70, indicating a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe IceCure Medical is more favorable than Modular Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IceCure Medical has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Modular Medical has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

In the previous week, IceCure Medical had 6 more articles in the media than Modular Medical. MarketBeat recorded 6 mentions for IceCure Medical and 0 mentions for Modular Medical. IceCure Medical's average media sentiment score of 0.35 beat Modular Medical's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Overall Sentiment
IceCure Medical	Neutral
Modular Medical	Neutral

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 7.1% of Modular Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Modular Medical has a net margin of 0.00% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat Modular Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
Modular Medical	N/A	-245.85%	-190.80%

Summary

IceCure Medical beats Modular Medical on 11 of the 15 factors compared between the two stocks.

Get IceCure Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCM vs. The Competition

Export

Metric	IceCure Medical	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.16M	$8.76B	$6.42B	$12.59B
Dividend Yield	N/A	1.73%	2.68%	5.81%
P/E Ratio	-0.75	24.73	24.78	24.44
Price / Sales	4.25	22.34	553.91	122.27
Price / Cash	N/A	102.97	45.07	55.09
Price / Book	1.45	5.64	10.80	6.58
Net Income	-$15.06M	$179.69M	$3.57B	$337.17M
7 Day Performance	125.94%	1.96%	0.72%	0.83%
1 Month Performance	-23.63%	2.99%	0.41%	2.25%
1 Year Performance	-81.08%	6.36%	29.34%	36.14%

IceCure Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCM IceCure Medical	2.9811 of 5 stars	$5.40 flat	$62.70 +1,061.1%	-81.1%	$15.16M	$3.57M	N/A	60	Gap Up
NMTC NeuroOne Medical Technologies	2.4411 of 5 stars	$3.38 -2.5%	$11.67 +245.7%	-16.9%	$29.09M	$12.10M	N/A	20
CTSO Cytosorbents	3.2534 of 5 stars	$0.44 +6.5%	$5.38 +1,118.8%	-62.9%	$27.69M	$37.20M	N/A	220	News Coverage Gap Up
PETV PetVivo	N/A	$0.73 +0.6%	N/A	+0.1%	$26.74M	$1.05M	N/A	20	Upcoming Earnings Gap Up
POAI Predictive Oncology	N/A	$7.32 -5.3%	N/A	-45.4%	$24.84M	$1.66M	N/A	30	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCM) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IceCure Medical (ICCM) Competitors

ICCM vs. NMTC, CTSO, PETV, POAI, and MODD

How does IceCure Medical compare to NeuroOne Medical Technologies?

Summary

How does IceCure Medical compare to Cytosorbents?

Summary

How does IceCure Medical compare to PetVivo?

Summary

How does IceCure Medical compare to Predictive Oncology?

Summary

How does IceCure Medical compare to Modular Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCM vs. The Competition

IceCure Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IceCure Medical (ICCM) Competitors

ICCM vs. NMTC, CTSO, PETV, POAI, and MODD

How does IceCure Medical compare to NeuroOne Medical Technologies?

Is ICCM or NMTC more profitable?

Do insiders and institutionals have more ownership in ICCM or NMTC?

Which has more volatility and risk, ICCM or NMTC?

Do analysts rate ICCM or NMTC?

Which has stronger earnings & valuation, ICCM or NMTC?

Does the media favor ICCM or NMTC?

Summary

How does IceCure Medical compare to Cytosorbents?

Do insiders and institutionals believe in ICCM or CTSO?

Is ICCM or CTSO more profitable?

Does the media refer more to ICCM or CTSO?

Which has better valuation and earnings, ICCM or CTSO?

Which has more volatility & risk, ICCM or CTSO?

Do analysts recommend ICCM or CTSO?

Summary

How does IceCure Medical compare to PetVivo?

Do insiders and institutionals hold more shares of ICCM or PETV?

Is ICCM or PETV more profitable?

Which has more volatility and risk, ICCM or PETV?

Which has better earnings & valuation, ICCM or PETV?

Does the media favor ICCM or PETV?

Do analysts recommend ICCM or PETV?

Summary

How does IceCure Medical compare to Predictive Oncology?

Is POAI or ICCM more profitable?

Which has more volatility & risk, POAI or ICCM?

Does the media favor POAI or ICCM?

Do analysts prefer POAI or ICCM?

Which has stronger earnings & valuation, POAI or ICCM?

Do insiders and institutionals have more ownership in POAI or ICCM?

Summary

How does IceCure Medical compare to Modular Medical?

Which has preferable earnings & valuation, ICCM or MODD?

Do analysts recommend ICCM or MODD?

Which has more risk and volatility, ICCM or MODD?

Does the media refer more to ICCM or MODD?

Do institutionals and insiders believe in ICCM or MODD?

Is ICCM or MODD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCM vs. The Competition

IceCure Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools